Study Demonstrates Feasibility of Tracking Mutations in Multiple Genes with Circulating Tumor DNA | GenomeWeb

NEW YORK (GenomeWeb News) – In Science Translational Medicine, researchers from the UK and the US have demonstrated the feasibility of doing blood-based 'liquid biopsies' using a targeted deep sequencing strategy that can uncover mutations in several genes using tumor DNA that is circulating in the bloodstream.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.